Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: Phase I evaluation

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4827-4834

  Thamm, Douglas H ^a,b,d   Kurzman, Ilene D ^a,b   King, Ivan ^c   Li, Zujin ^c   Sznol, Mario ^c,e   Dubielzig, Richard R ^a   Vail, David M ^a,b,d   MacEwen, E Gregory ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Vion Pharmaceuticals Incorporated   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CLINICAL FEATURE; COLONY FORMING UNIT; CONTROLLED STUDY; DEATH; DNA MODIFICATION; DOG; FEMALE; FEVER; GENE DELIVERY SYSTEM; HISTOPATHOLOGY; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; TARGET CELL DESTRUCTION; TUMOR BIOPSY; VOMITING;

ANIMALS; DIARRHEA; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; MALE; NEOPLASMS; SALMONELLA TYPHIMURIUM; TREATMENT OUTCOME; VACCINES, ATTENUATED; VOMITING;

EID: 27644526910     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2510     Document Type: Article

References (39)

1. Coley WB. Late results of the treatment of inoperable sarcoma by the mixed toxins of Erysipelas and Bacillus prodigosus. Am J Med Sci 1906;131:375-430.
2. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop 1991;262:3-11.
3. Coley WB, Hoguet JP. Melanotic cancer. Ann Surg 1916;64:206-41.
4. Mose JR, Mose G. Oncolysis by Clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic Clostridia against the Ehrlich carcinoma. Cancer Res 1964;24:212-6.
5. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997;57:4537-44.
6. Galan JE, Collmer A. Type III secretion machines: bacterial devices for protein delivery into host cells. Science 1999;284:132-8.
7. Sukhan A. The invasion-associated type III secretion system of Salmonella typhimurium: common and unique features. Cell Mol Life Sci 2000;57:1033-49.
8. Norimatsu M, Chance V, Dougan G, et al. Live Salmonella enterica serovar Typhimurium (S. Typhimurium) elicit dendritic cell responses that differ from those induced by killed S. Typhimurium. Vet Immunol Immunopathol 2004;98:193-201.
9. Wyant TL, Tanner MK, Sztein MB. Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes. Infect Immun 1999;67:3619-24.
10. Tjuvajev J, Blasberg R, Luo X, et al. Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging. J Control Release 2001;74:313-5.
11. Nemunaitis J, Cunningham C, Senzer N, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003;10:737-44.
12. Niethammer AG, Primus FJ, Xiang R, et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine 2001;20:421-9.
13. Saltzman DA, Heise CP, Hasz DE, et al. Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel antitumor agent. Cancer Biother Radiopharm 1996;11:145-53.
14. Urashima M, Suzuki H, Yuza Y, et al. An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood 2000;95:1258-63.
15. Xiang R, Lode HN, Chao TH, et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A 2000;97:5492-7.
16. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002;25:218-25.
17. Sznol M, Lin SL, Bermudes D, et al. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest 2000;105:1027-30.
18. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol 1999;17:37-41.
19. Somerville JEJ, Cassiano R, Darveau RP. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect Immun 1999;67(12):6583-90.
20. Luo X, Li Z, Lin S, et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res 2000;12:501-8.
21. Soto LJ III, Sorenson BS, Kim AS, et al. Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. J Pediatr Surg 2003;38:1075-9.
22. Platt J, Sodi S, Kelley M, et al. Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur J Cancer 2000;36:2397-402.
23. Zheng LM, Luo X, Feng M, et al. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol Res 2000;12:127-35.
24. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20:142-52.
25. Heimann DM, Rosenberg SA. Continuous intravenous administration of live genetically modified Salmonella typhimurium in patients with metastatic melanoma. J Immunother 2003;26:179-80.
26. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004;40:858-80.
27. Vail DM, Thamm DH. Spontaneously occurring tumors in companion animals as models for drug development. In: Teicher BA, Andrews PA, editors. Anticancer drug development guide: preclinical screening, clinical trials, and approval. 2nd ed. Totowa (NJ): Humana Press; 2004. p. 259-84.
28. Veterinary Cooperative Oncology Group. Veterinary Cooperative Oncology Group: common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004;2:194-213.
29. MacPhail CM, Lappin MR, Meyer DJ, et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 1998;212:1895-901.
30. MacEwen EG. Hemangiosarcoma. In: Withrow SJ, MacEwen EG, editors. Small animal clinical oncology. 3rd ed. Philadelphia: Saunders; 2003. p. 639-45.
31. Bowles AP Jr, Perkins E. Long-term remission of malignant brain tumors after intracranial infection: a report of four cases. Neurosurgery 1999;44:636-42; discussion 42-3.
32. Miller TR, Nicholson JT. End results in reticulum cell sarcoma of bone treated by bacterial toxin therapy alone or combined with surgery and-or radiotherapy (47 cases) or with concurrent infection (5 cases). Cancer 1971;27:524-48.
33. Papachristou DN, Fortner JG. Effect of postoperative wound infection on the course of stage II melanoma. Cancer 1979;43:1106-11.
34. Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med 1972;287:1013-7.
35. Takita H. Effect of postoperative empyema on survival of patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg 1970;59:642-4.
36. Withrow SJ, Liptak JM, Straw RC, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol 2004;11:705-13.
37. Bannerman DD, Goldblum SE. Mechanisms of bacterial lipopolysaccharide- induced endothelial apoptosis. Am J Physiol Lung Cell Mol Physiol 2003;284:L899-914.
38. Hunter CA, Yu D, Gee M, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol 2001;166:5878-81.
39. Rankin EB, Yu D, Jiang J, et al. An essential role of Th1 responses and interferon γ in infection-mediated suppression of neoplastic growth. Cancer Biol Ther 2003;2:687-93.